Cascadian Therapeutics Inc.
(NASDAQ : CASC)

( )
CASC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.04%108.241.1%$605.41m
GILDGilead Sciences, Inc.
-2.93%74.340.9%$540.78m
AMGNAmgen Inc.
-1.39%174.921.1%$476.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%383.122.7%$338.65m
BIIBBiogen Inc.
-2.17%323.551.2%$316.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.40%113.091.9%$255.42m
BLUEBluebird Bio, Inc.
-0.30%184.3516.1%$198.90m
VRTXVertex Pharmaceuticals Incorporated
-1.57%142.531.9%$197.41m
ILMNIllumina, Inc.
-1.73%210.853.5%$160.91m
ALNYAlnylam Pharmaceuticals, Inc
-0.96%123.6610.0%$160.42m
NKTRNektar Therapeutics
-2.79%55.056.1%$153.38m
AAgilent Technologies, Inc.
-0.26%66.511.5%$152.00m
INCYIncyte Corporation
-2.17%95.972.5%$129.88m
BMRNBioMarin Pharmaceutical Inc.
-0.15%88.534.4%$100.67m
JUNOJuno Therapeutics, Inc.
-6.83%44.1713.5%$94.92m

Company Profile

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA